Abstract 795MO
Background
Treatment options for previously treated, advanced MSI-H or mismatch repair deficient (dMMR) tumors are limited. Pembro showed durable and clinically meaningful benefit in previously treated, advanced MSI-H/dMMR tumors, including EC, in the nonrandomized, open-label, phase II KEYNOTE-158 study (NCT02628067). ORR of 57% was observed in 49 pts with MSI-H/dMMR EC in KEYNOTE-158. We present longer follow up in more pts from KEYNOTE-158.
Methods
Pts from cohorts D (EC, regardless of MSI-H status) and K (any MSI-H/dMMR solid tumor, except colorectal) were ≥18 y, had previously treated, advanced MSI-H/dMMR EC, measurable disease per RECIST v1.1, ECOG PS 0/1 and provided a tumor sample for biomarker analysis. In cohort D, MSI-H expression was determined retrospectively by PCR at a central lab. In cohort K, MSI-H/dMMR output was determined prospectively by PCR and/or IHC at a local lab, respectively. Pts received pembro 200 mg Q3W for up to 35 cycles. Primary endpoint was ORR per RECIST v1.1 by independent central radiologic review. Secondary endpoints included DOR, PFS, OS, and safety. Efficacy was assessed in pts who received ≥1 pembro dose and had ≥26 wk follow up; and safety in all treated pts.
Results
As of Oct 5, 2020, 18/90 pts (20%) had completed 35 cycles of pembro and 52 (58%) had discontinued treatment. In the efficacy population (n = 79), median time from first dose to data cutoff was 42.6 (range, 6.4–56.1) mo; 41 (52%) had ≥2 lines of prior therapy and 61% had ECOG PS 1. ORR was 48%, with DOR ≥3 y in 68%; see the table for results. 68/90 pts (76%) had treatment-related AEs (grade 3–4, 12%; no grade 5), and led to discontinuation in 7%. 25 pts (28%) had immune-mediated AEs and infusion reactions (grade 3–4, 7%; no grade 5).
Conclusions
Pembro demonstrated robust and durable ORR (48%; CR, 14%), encouraging survival outcomes and manageable toxicity in pts with heavily pretreated, advanced MSI-H/dMMR EC, and is a promising treatment option in this setting. Table: 795MO
Efficacy Population (n = 79) | |
ORR, % (95% CI) | 48 (36.7 to 59.6) |
CR, n (%) | 11 (14) |
PR, n (%) | 27 (34) |
SD, n (%) | 14 (18) |
DOR median (range), mo | NR (2.9 to 49.7+) |
DOR ≥1 y, % | 88 |
DOR ≥2 y, % | 73 |
DOR ≥3 y, % | 68 |
Median PFS, mo (95% CI) | 13.1 (4.3 to 34.4) |
3-y PFS rate, % | 37 |
Median OS, mo (95% CI) | NR (27.2 to NR) |
3-y OS rate, % | 60 |
NR, not reached. “+” indicates there was no PD by the time of last disease assessment. |
Clinical trial identification
NCT02628067.
Editorial acknowledgement
Writing support was provided by Christabel Wilson, MSc, of ICON plc (North Wales, PA, USA), funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Legal entity responsible for the study
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Funding
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
D. O'Malley: Financial Interests, Personal, Advisory Board: AstraZeneca, Tesaro/GSK, BBI, Immunogen, Ambry, Janssen/J&J, Abbvie, Regeneron, Amgen, Novocure, Genentech/Roche, GOGFoundation, Iovance Biotherapeutics, Inc, Myriad Genetics, Eisai, Agenus, Tarveda, Merck & Co., Inc., Kenilworth, NJ, USA, SeaGen, Novart; Financial Interests, Institutional, Funding: AstraZeneca, Tesaro/GSK, Immunogen, Janssen/J&J, Abbvie, Regeneron, Amgen, Novocure, Genentech/Roche, VentiRx, Array Biopharma, EMD Serono, Ergomed, Ajinomoto Inc., Ludwig Cancer Research, Stemcentrx, Inc, Cerulean Pharma, GOGFoundation, NCI, Bristol Mye. G.M. Bariani: Financial Interests, Personal, Funding: Mabxience; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Bristol Myers Squibb; Financial Interests, Personal, Advisory Role: Libbs. P.A. Cassier: Financial Interests, Personal, Funding: Roche/Genentech; Novartis; Amgen; Bristol Myers Squibb; Blueprint Medicines; GlaxoSmithKline; Janssen; Eli Lilly; Taiho Pharmaceutical; AstraZeneca; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Celgene; AbbVie; Toray ; Financial Interests, Personal, Other, Personal fees: Roche/Genentech; Novartis; Amgen; Merck Serono; and AstraZeneca; Non-Financial Interests, Personal, Other, Nonfinancial support: Roche/Genentech; Novartis; AstraZeneca; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; and Plexxikon; Financial Interests, Personal, Other, Travel accommodations: Netris Pharma. A. Marabelle: Financial Interests, Institutional, Funding: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD); Financial Interests, Personal, Other, Honorarium: MSD; Financial Interests, Personal, Research Grant: Fondation de l’Avenir and Bristol Myers Squibb; Financial Interests, Speaker’s Bureau: Bristol Myers Squibb and MSD. A.R. Hansen: Financial Interests, Personal, Advisory Role: Genentech/Roche, Merck & Co., GSK, Bristol Myers Squibb, Novartis, Boehringer Ingelheim, AstraZeneca, MedImmune; Financial Interests, Personal, Funding: Genentech/Roche, Merck & Co., GSK, Bristol Myers Squibb, Novartis, Boehringer Ingelheim, AstraZeneca, MedImmune, Boston Medical. A. De Jesus Acosta: Financial Interests, Personal, Funding: AstraZeneca; Merck & Co., Inc., Kenilworth, NJ, USA; Financial Interests, Personal, Other, Consultancy: Merck & Co., Inc., Kenilworth, NJ, USA. W.H. Miller, Jr: Financial Interests, Personal, Other, Personal fees for serving as a consultant: BMS, Merck & Co., Inc., Kenilworth, NJ, USA, Roche, Novartis, Amgen, GSK, and Sanofi. A. Italiano: Financial Interests, Personal, Funding: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; AstraZeneca; Merck Serono; and Bayer; Financial Interests, Personal, Other, Personal fees: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; AstraZeneca; Bayer; Bristol Myers Squibb; Epizyme; and Roche. L. Xu: Financial Interests, Personal, Full or part-time Employment: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc., Kenilworth, NJ, USA. F. Jin: Financial Interests, Personal, Full or part-time Employment: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc., Kenilworth, NJ, USA. K. Norwood: Financial Interests, Personal, Full or part-time Employment: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc., Kenilworth, NJ, USA. M. Maio: Financial Interests, Personal, Advisory Board: Roche; Bristol Myers Squibb; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Incyte; AstraZeneca; Amgen; Pierre Fabre; Eli Lilly; GlaxoSmithKline; Sanofi; Alfasigma; Merck Serono; Financial Interests, Personal, Other, Honoraria: Roche, Bristol Myers Squibb; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; AstraZeneca; Amgen; Pierre Fabre; Eli Lilly; GlaxoSmithKline; Sciclone; Sanofi; Alfasigma; Merck Serono; Financial Interests, Personal, Stocks/Shares: Epigen Therapeutics, and Theravance. All other authors have declared no conflicts of interest.
Resources from the same session
723MO - Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study
Presenter: Ignace Vergote
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
724MO - Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC)
Presenter: David O'Malley
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
725MO - Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer
Presenter: Susana Banerjee
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
726MO - Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)
Presenter: Nicoletta Colombo
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
LBA34 - Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004
Presenter: Joyce Liu
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Discussion 725MO and 726MO
Presenter: David SP Tan
Session: Mini oral session - Gynaecological cancers
Resources:
Slides
Webcast
Discussion LBA34 and 795MO
Presenter: Naveena Singh
Session: Mini oral session - Gynaecological cancers
Resources:
Slides
Webcast
Discussion 723MO and 724MO
Presenter: Ana Oaknin
Session: Mini oral session - Gynaecological cancers
Resources:
Slides
Webcast